loading...| Preferred Name |
sirolimus |
|
| Synonyms |
Rapamune |
|
| Definitions |
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1212" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1212" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042555 |
|
| altLabel |
Rapamune WY-090217 rapamycin AY 22989 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2 SILA 9268A SLM RAPA |
|
| CAS Registry |
53123-88-9 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000380452 http://purl.bioontology.org/ontology/PDQ/CDR0000042556 http://purl.bioontology.org/ontology/PDQ/CDR0000406030 http://purl.bioontology.org/ontology/PDQ/CDR0000355816 http://purl.bioontology.org/ontology/PDQ/CDR0000415241 http://purl.bioontology.org/ontology/PDQ/CDR0000355817 |
|
| cui |
C0813828 C0072980 C1710099 C1710098 C0878382 |
|
| Date last modified |
2006-05-10 |
|
| definition |
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1212" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1212" NCI Thesaurus) |
|
| Legacy PDQ ID |
2015-08-17 |
|
| LT |
TRD |
|
| NCI ID |
C1212 |
|
| notation |
CDR0000042555 |
|
| NSC Code |
226080 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
sirolimus |
|
| tui |
T109 T195 |